effect overlay
activetrials
Epilepsy
Epilepsy
PNES

Psychological and cultural aspects of psychogenic non-epileptic seizures (PNES)
 

HREC: 2012.030
Principal Investigator: Prof Terry O'Brien
Coordinator contact:
Funding: Non-Commercial
Dementia
Dementia
RETHINK

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects With Mild-to-Moderate Alzheimer’s Disease
 

HREC: 2022.215
Principal Investigator: Dr Christopher Kyndt
Coordinator contact: Lesley-Anne Attard
Funding: Commercial
Dementia
Dementia
TRAILBLAZER - Donanemab in Alzheimer's

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
 

HREC: 2021.066
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia
Dementia
EP004 - Anavex OLE

Open Label Extension Study for Patients with Early Alzheimer’s Disease (AD) Enrolled in Study ANAVEX2-73-AD-004
 

HREC: 2020.257
Principal Investigator: Prof Amy Brodtmann
Coordinator contact: Sophie Robinson
Funding: Commercial
Dementia
Dementia
SELENATE 002

A Phase 2b Randomised Controlled Trial of Sodium Selenate as a Disease Modifying Treatment for Probably Behavioural Variant Fronto-temporal Dementia
 

HREC: 2020.171
Principal Investigator: Prof Dennis Velakoulis
Coordinator contact: Lauren Martell
Funding: Non-Commercial